Okklo life sciences BV is a privately held biopharmaceutical company developing novel therapeutic solutions using cyclodextrin-based technologies.
The current programs are focussed on lysosomal storage disorders and cardiovascular disorders.
The company was founded in December 2011 by a group of life-sciences experts previously involved in the development and approval of sugammadex (Bridion™), the first modified cyclodextrin marketed as a drug product.
We are continuously looking for collaborations and partnering opportunities with public and private partners - please visit our website to learn more about our technology platform strategy and development pipeline.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Transistorweg 5, Nijmegen,6534 At,netherlands
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- okklo.com
- HQ
- Nijmegen
Okklo Life Sciences Questions
Okklo Life Sciences's website is okklo.com
Okklo Life Sciences's LinkedIn profile is https://nl.linkedin.com/company/okklo-life-sciences
Okklo Life Sciences has
3 employees.
View email and phone details for 3
employees at Okklo Life Sciences.
Okklo Life Sciences's industry is
Pharmaceutical Manufacturing
Okklo Life Sciences's top competitors are
Mdxhealth,
Binnovate Digital,
Pinkrf - The Rf Energy Company,
Alveron Pharma,
Medip Analytics,
Saillant Therapeutics,
Pharmacytics,
Vaxxinova,
Innogreen-Chem Bv,
Enzyre B.v..
Okklo Life Sciences's categories are Pharmaceutical Manufacturing
Okklo Life Sciences's founding year is 2011
